Alvogen Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 5.50 M
as on 16-11-2024
- Paid Up Capital ₹ 5.12 M
as on 16-11-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 23.65%
(FY 2023)
- Profit 205.00%
(FY 2023)
- Ebitda 128.99%
(FY 2023)
- Net Worth 41.24%
(FY 2023)
- Total Assets 13.99%
(FY 2023)
About Alvogen Pharma (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.50 M and a paid-up capital of Rs 5.12 M, as per Ministry of Corporate Affairs (MCA) records.
Saral Thangam, Fjalar Kristjansson, Divya Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U74900KA2010PTC053204
- Company No.
053204
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Alvogen Pharma (India)?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saral Thangam  | Director | 20-Sep-2014 | Current |
Fjalar Kristjansson  | Director | 13-Apr-2010 | Current |
Divya Patel  | Nominee Director | 01-May-2010 | Current |
| Aditya Bellur | Director | 13-Dec-2017 | Current |
Financial Performance of Alvogen Pharma (India).
Alvogen Pharma (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 23.65% increase. The company also saw a substantial improvement in profitability, with a 205% increase in profit. The company's net worth Soared by an impressive increase of 41.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alvogen Pharma (India)?
In 2023, Alvogen Pharma (India) had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Norwich Clinical Services Private LimitedActive 15 years 1 monthSaral Thangam, Fjalar Kristjansson and 2 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Alvogen Pharma (India)?
Alvogen Pharma (India) has a workforce of 31 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alvogen Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alvogen Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
